125 filings
6-K
GMAB
Genmab
21 Dec 20
Current report (foreign)
10:25am
6-K
GMAB
Genmab
15 Dec 20
Current report (foreign)
5:17pm
6-K
GMAB
Genmab
24 Nov 20
Genmab Announces Enapotamab Vedotin Update
11:59am
6-K
GMAB
Genmab
12 Nov 20
Current report (foreign)
9:54am
6-K
GMAB
Genmab
10 Nov 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:04pm
6-K
gzcybzqze66hiv7zml
5 Nov 20
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11:06am
6-K
aby4wh yg9t0
4 Nov 20
Genmab Announces Financial Results for the First Nine Months of 2020
11:48am
6-K
mwgk5c
21 Oct 20
Current report (foreign)
5:06pm
6-K
7ilt t26qlh7ut1j
15 Oct 20
Current report (foreign)
11:09am
6-K
aqvrm
14 Oct 20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
4:54pm
6-K
luogly4c 6ukt
7 Oct 20
Current report (foreign)
5:15pm
6-K
n02n25z
30 Sep 20
Current report (foreign)
2:06pm
6-K
lcr ou650qoaq
30 Sep 20
Current report (foreign)
10:49am
6-K
lg5aozl0tsfi wg9s
30 Sep 20
Current report (foreign)
12:00am
6-K
ql32n
29 Sep 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:02pm
6-K
muwu2p8p2kaknxr41ut
22 Sep 20
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
5:14pm
6-K
1qf3076wcfm43n
20 Aug 20
Current report (foreign)
5:29pm
6-K
egv92cv1wofclhakaj7e
20 Aug 20
Current report (foreign)
5:24pm
6-K
v6qh7rm
20 Aug 20
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2:19pm
6-K
n4q h2h2g538
19 Aug 20
Current report (foreign)
10:59am